Senseonics Q4 ’19 Earnings Update
Senseonics hosted its Q4 ’19 earnings call (press release) and provided updates to its Eversense implantable CGM commercial and pipeline activities. Of note, the iCGM designation filing for the 90-day Eversense CGM is now anticipated in Q2 ’20. Below, FENIX provides highlights and insights from the call.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.